Revenue and Core Growth
Total sales of $706 million in Q1 FY2026; reported core sales growth of 9.5% year-over-year, with normalized core growth of ~4% after adjusting for 4 extra billing days ($28M, ~4.5% impact) and Spark deferral benefits.
Strong Margin Expansion and Profitability
Adjusted gross margin expanded to 55.8%, up 100 basis points year-over-year; adjusted EBITDA rose 25% YoY with margin of 14%, up 120 basis points; adjusted EPS was $0.36 (up $0.12 YoY, ~50% growth).
Segment Outperformance — Specialty Products & Technology
Specialty Products & Technology revenue grew >14% YoY with core sales up 8.4%; adjusted operating profit increased $10 million YoY (+18%) with a 40-basis-point improvement in operating margin; ortho (Spark and Brackets & Wires) drove double-digit growth.
Segment Outperformance — Equipment & Consumables
Equipment & Consumables core sales rose 11.5% YoY with double-digit growth in consumables and diagnostics; adjusted operating profit grew 33% YoY and operating margins improved nearly 300 basis points, driven by pricing and volume.
Volume, Pricing and Product Innovation Mix
Volume contributed over 7 percentage points of Q1 growth with price contributing ~2+ points; notable new-product launches include Nobel S Series (implants with >25% of orders from competitive conversions), Spark launch in Japan, and DEXIS DTX Studio Clinic with enhanced AI (DEXIS installed base ~275K devices processing ~500M images/year).
Accretive M&A and Portfolio Strengthening
Completed tuck-in acquisition of Versah (osseodensification technology) expected to be accretive to growth, margin, EPS and valuation multiple; three small acquisitions over past year strengthened implants and international presence.
Balance Sheet, Cash Return and Capital Allocation
Net debt to adjusted EBITDA below 1x; repurchased ~1.6 million shares in Q1 and had $41 million remaining repurchase capacity at quarter-end before today's authorization; Board authorized incremental $300 million share repurchase program through 2029 while reaffirming organic and M&A priorities.
Tax Rate and FX Tailwinds
Non-GAAP tax rate improved to 26.1% in Q1 (better than expectations), helped by resolution of a legacy intercompany loan; foreign exchange contributed roughly $26 million in revenue and was a tailwind to adjusted EBITDA (~$7M).